← Back to Search

Cryoablation

Cryoablation-Assisted Surgery for Kidney Cancer (RCAPN Trial)

N/A

Recruiting

Led By Fernando J Bianco, MD

Research Sponsored by Urological Research Network, LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with ages between 45-90-year-old

Renal tumor ≤ 7 cm in the greatest extension, >50% exophitic

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 years

Awards & highlights

RCAPN Trial Summary

This trial will compare two methods of controlling blood loss during surgery for kidney cancer: renal cryoablation (freezing the tumor) and selective arterial renal ischemia (restricting blood flow to the kidney).

Who is the study for?

This trial is for individuals aged 45-90 with kidney tumors that are less than 7 cm large and mostly on the outside of the kidney. It's not suitable for those who've had previous kidney surgery or have metastatic disease, where cancer has spread to other parts of the body.Check my eligibility

What is being tested?

The study tests a new method called Cryoablation Assisted Partial Nephrectomy in patients with renal masses. This technique might help control blood loss during surgery without stopping blood flow to the kidney, which is usually done by arterial ischemia.See study design

What are the potential side effects?

While specific side effects aren't listed here, cryoablation procedures can typically include pain at the treatment site, bleeding, infection risks, and potential damage to nearby tissues or organs.

RCAPN Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 45 and 90 years old.

Select...

My kidney tumor is 7 cm or smaller and mostly on the outside of the kidney.

RCAPN Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Recurrence - Oncological Control

Secondary outcome measures

Development or Progression of Chronic Kidney Disease (CKD)

Incidence of Metastatic disease

Local Re-Intervention

+1 more

RCAPN Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment groupExperimental Treatment1 Intervention

Patients underwent Cryotheapy assisted partial nephrectomy

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Urological Research Network, LLCLead Sponsor

4 Previous Clinical Trials

10,040 Total Patients Enrolled

Fernando J Bianco, MDPrincipal InvestigatorUrological research Network

1 Previous Clinical Trials

20 Total Patients Enrolled

Media Library

Cryoablation Assisted Partial Nephrectomy (Cryoablation) Clinical Trial Eligibility Overview. Trial Name: NCT05218811 — N/A

Kidney Tumors Research Study Groups: Treatment group

Kidney Tumors Clinical Trial 2023: Cryoablation Assisted Partial Nephrectomy Highlights & Side Effects. Trial Name: NCT05218811 — N/A

Cryoablation Assisted Partial Nephrectomy (Cryoablation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05218811 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this research protocol for volunteers?

"According to the information available on clinicaltrials.gov, this experiment is currently looking for participants and has been since it was initially posted back in May of 2020 with its most recent update occurring at the end of January 2022."

Answered by AI

Does this trial accept individuals aged 55 or older as participants?

"This medical study seeks out participants aged between 55 and 65 years old. 19 trials are available for persons below the age of majority, while 145 studies cater to more elderly patients."

Answered by AI

Are there any restrictions for prospective participants in this medical trial?

"The trial is welcoming 150 seniors, aged 55 to 65, with renal neoplasms. Additional prerequisites include the following: Patients within an age range of 45-90 years old., Renal tumor no larger than 7 cm in its longest axis and >50% exophitic.."

Answered by AI

What is the approximate size of the cohort taking part in this investigation?

"Affirmative. According to information available from clinicaltrials.gov, this medical study began recruiting on May 15th 2020 and is still actively searching for participants. There are 150 spots open at a single research centre."

Answered by AI

Recent research and studies

Scandinavian Journal of UrologyJournal

Renal Cryoablation – Does Deep Endophytic Ablation Affect the Renal Collecting System?

Makki, Ahmad, Malene B. Aastrup, Hanne Vinter, Bodil Ginnerup, Ole Graumann, Michael Borre, and Tommy Kjaergaard Nielsen. 2019. “Renal Cryoablation – Does Deep Endophytic Ablation Affect the Renal Collecting System?”. Scandinavian Journal of Urology. Informa UK Limited. doi:10.1080/21681805.2019.1702094.

Current Opinion in UrologyJournal

Cryoablation for Renal Tumors: Current Status

Berger, Andre, Kazumi Kamoi, Inderbir S Gill, and Monish Aron. 2009. “Cryoablation for Renal Tumors: Current Status”. Current Opinion in Urology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/mou.0b013e328323f618.

European UrologyJournal

Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results

Zargar, Homayoun, Thomas D. Atwell, Jeffrey A. Cadeddu, Jean J. de la Rosette, Gunther Janetschek, Jihad H. Kaouk, Surena F. Matin, Thomas J. Polascik, Kamran Zargar-Shoshtari, and R. Houston Thompson. 2016. “Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results”. European Urology. Elsevier BV. doi:10.1016/j.eururo.2015.03.027.

CardioVascular and Interventional RadiologyJournal